<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01620242</url>
  </required_header>
  <id_info>
    <org_study_id>UC-0130/1106</org_study_id>
    <secondary_id>2011-004712-32</secondary_id>
    <nct_id>NCT01620242</nct_id>
  </id_info>
  <brief_title>A Phase II, Open-Label, Multicenter Trial of Cabazitaxel in Patients With Recurrent or Metastatic Head and Neck Cancer After Failure Of Cisplatin, Cetuximab and Taxanes</brief_title>
  <acronym>ORL03</acronym>
  <official_title>A PHASE II, OPEN-LABEL, MULTICENTER TRIAL OF CABAZITAXEL IN PATIENTS WITH RECURRENT OR METASTATIC HEAD AND NECK CANCER AFTER FAILURE OF CISPLATIN, CETUXIMAB AND TAXANES.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UNICANCER</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center phase II study assessing whether cabazitaxel could be efficient for&#xD;
      treatment of recurrent or metastatic head and neck cancer after failure of cisplatin,&#xD;
      cetuximab and taxanes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be treated with intravenous cabazitaxel 25 mg/m2 every 3 weeks (D1=D22) for 6&#xD;
      cycles.&#xD;
&#xD;
      In absence of progression disease or unacceptable toxicity, the treatment could be continued&#xD;
      until a maximum of 10 cycles.&#xD;
&#xD;
      Disease response will be assessed every 6 weeks (i.e. every 2 cycles) clinically and by&#xD;
      CT-scan.&#xD;
&#xD;
      An interim analysis will be carried out after the inclusion of the first 10 eligible and&#xD;
      assessable patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">May 27, 2014</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>non-progression at 6 weeks</measure>
    <time_frame>6 weeks</time_frame>
    <description>To assess the efficacy of cabazitaxel in terms of non-progression at 6 weeks for the treatment of recurrent or metastatic head and neck cancer after failure of cisplatin, cetuximab and taxanes.&#xD;
Non-progression will be assessed after centralized review of CT-scans.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>1-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity according to NCI-CTCAE v4.0</measure>
    <time_frame>from the first dose up to 30 days after the last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life evaluated by the QLQ-C30 and H&amp;N35 questionnaire</measure>
    <time_frame>at the inclusion, at 6 weeks and at the end of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Recurrent Head and Neck Cancer</condition>
  <condition>Metastatic Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>Cabazitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients are treated with Cabazitaxel.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cabazitaxel</intervention_name>
    <description>25 mg/m2 every 3 weeks by IV administration</description>
    <arm_group_label>Cabazitaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Metastatic or recurrent Head and neck cancer&#xD;
&#xD;
          2. Progression after cisplatin, cetuximab and taxanes (drugs could have been administered&#xD;
             alone or in combination) given for recurrent/metastatic disease&#xD;
&#xD;
          3. Age ≥ 18&#xD;
&#xD;
          4. ECOG performance status ≤ 2&#xD;
&#xD;
          5. At least one measurable lesion on CT-scan (as per RECIST criteria V1.1).&#xD;
&#xD;
          6. Life expectancy ≥ 3 months&#xD;
&#xD;
          7. Adequate hematologic function (neutrophils ≥ 1.5 x 109/L, platelets ≥ 100 x 109/L; Hb&#xD;
             ≥ 9.0 g/dL), renal function (clearance creatinine using the CKD-EPI formula (Chronic&#xD;
             Kidney Disease Epidemiology group) ≥ 60 mL/min) and hepatic function (serum bilirubin&#xD;
             ≤ 1 ULN; AST and ALT ≤ 2.5 x ULN).&#xD;
&#xD;
          8. Potentially reproductive patients must agree to use an effective contraceptive method&#xD;
             while on treatment, beginning 2 weeks before the first dose of investigational product&#xD;
             and for 6 months after the final dose of investigational product.&#xD;
&#xD;
          9. Women of childbearing potential must have a negative serum beta-HCG pregnancy test&#xD;
             within 14 days prior of enrolment and/or urine pregnancy test within 48 hours before&#xD;
             the first administration of the study treatment.&#xD;
&#xD;
         10. Patients must be affiliated to a Social Security System.&#xD;
&#xD;
         11. Patient who have received the information sheet and signed the informed consent form.&#xD;
&#xD;
         12. Patients must be willing and able to comply with scheduled visits, treatment plan,&#xD;
             laboratory tests and other study procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Active concurrent malignancy&#xD;
&#xD;
          2. Progression in the 3 months after the completion of treatment for localized disease&#xD;
&#xD;
          3. Patients with other concurrent severe and/or uncontrolled medical disease which could&#xD;
             compromise participation in the study, such as :&#xD;
&#xD;
               -  infection,&#xD;
&#xD;
               -  cardiac disease such as uncontrolled hypertension, congestive cardiac failure,&#xD;
                  ventricular arrhythmias, active ischemic heart disease, myocardial infarction&#xD;
                  within one year, LVEF &gt; grade 2,&#xD;
&#xD;
               -  current active hepatic or biliary disease (with exception of subjects with&#xD;
                  Gilbert's syndrome, asymptomatic gallstones, liver metastasis or stable chronic&#xD;
                  liver disease per investigator assessment),&#xD;
&#xD;
               -  renal disease,&#xD;
&#xD;
               -  active GI tract ulceration, malabsorption syndrome, disease significantly&#xD;
                  affecting gastrointestinal function, or resection of the stomach or small bowel.&#xD;
                  Subjects with active, uncontrolled ulcerative colitis are also excluded,&#xD;
&#xD;
               -  severely impaired lung function (spirometry and DLCO 70% or less of normal and O2&#xD;
                  saturation of 88% or less at rest on room air).&#xD;
&#xD;
          4. Patients must have recovered of previous toxicity of chemotherapy and must not have&#xD;
             toxicity grade &gt; 1 ; grade ≥ 2 for neuropathy and grade ≥ 2 for cutaneous rash after&#xD;
             cetuximab (in the CTCAE v4.0)&#xD;
&#xD;
          5. Hypersensitivity to cabazitaxel, to other taxanes, or to any excipients of the&#xD;
             formulation including polysorbate 80&#xD;
&#xD;
          6. Pregnant women, women who are likely to become pregnant or are breast-feeding.&#xD;
&#xD;
          7. Patients with significantly altered mental status prohibiting the understanding of the&#xD;
             study or with psychological, familial, sociological or geographical condition&#xD;
             potentially hampering compliance with the study protocol and follow-up schedule; those&#xD;
             conditions should be discussed with the patient before registration in the trial.&#xD;
&#xD;
          8. Patients who received any other investigational drugs within the 14 days prior to the&#xD;
             start of cabazitaxel.&#xD;
&#xD;
          9. Patients receiving radiation within 4 weeks prior to the first dose of study drug.&#xD;
&#xD;
         10. Patients already included in another therapeutic trial involving an experimental drug&#xD;
&#xD;
         11. Individual deprived of liberty or placed under the authority of a tutor.&#xD;
&#xD;
         12. Other primary tumors within the previous 3 years&#xD;
&#xD;
         13. Concomitant prohibited treatment. Concurrent or planned treatment with strong&#xD;
             inhibitors or strong inducers of cytochrome P450 3A4/5. A one week wash-out period is&#xD;
             necessary for patients who are already on these treatments.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Léon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75231</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>May 24, 2012</study_first_submitted>
  <study_first_submitted_qc>June 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2012</study_first_posted>
  <last_update_submitted>February 25, 2021</last_update_submitted>
  <last_update_submitted_qc>February 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent or metastatic head and neck cancer</keyword>
  <keyword>cabazitaxel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>IPD will not be shared at an individual level, those data will be part of the study database including all enrolled patients.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

